Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H27F2N4O8P |
Molecular Weight | 580.4744 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O)OC3=CC=CC=C3)C(=O)OCC4=CC=CC=C4
InChI
InChIKey=NHTKGYOMICWFQZ-BBOXMAMFSA-N
InChI=1S/C25H27F2N4O8P/c1-16(22(33)36-14-17-8-4-2-5-9-17)30-40(35,39-18-10-6-3-7-11-18)37-15-19-21(32)25(26,27)23(38-19)31-13-12-20(28)29-24(31)34/h2-13,16,19,21,23,32H,14-15H2,1H3,(H,30,35)(H2,28,29,34)/t16-,19+,21+,23+,40-/m0/s1
Molecular Formula | C25H27F2N4O8P |
Molecular Weight | 580.4744 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. | 2012 Nov |
|
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. | 2014 Feb 27 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:12:31 GMT 2023
by
admin
on
Sat Dec 16 14:12:31 GMT 2023
|
Record UNII |
I17GWP65CE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
644618
Created by
admin on Sat Dec 16 14:12:31 GMT 2023 , Edited by admin on Sat Dec 16 14:12:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
I17GWP65CE
Created by
admin on Sat Dec 16 14:12:31 GMT 2023 , Edited by admin on Sat Dec 16 14:12:31 GMT 2023
|
PRIMARY | |||
|
1562406-27-2
Created by
admin on Sat Dec 16 14:12:31 GMT 2023 , Edited by admin on Sat Dec 16 14:12:31 GMT 2023
|
PRIMARY | |||
|
C102752
Created by
admin on Sat Dec 16 14:12:31 GMT 2023 , Edited by admin on Sat Dec 16 14:12:31 GMT 2023
|
PRIMARY | |||
|
134812042
Created by
admin on Sat Dec 16 14:12:31 GMT 2023 , Edited by admin on Sat Dec 16 14:12:31 GMT 2023
|
PRIMARY | |||
|
10748
Created by
admin on Sat Dec 16 14:12:31 GMT 2023 , Edited by admin on Sat Dec 16 14:12:31 GMT 2023
|
PRIMARY | |||
|
SUB197450
Created by
admin on Sat Dec 16 14:12:31 GMT 2023 , Edited by admin on Sat Dec 16 14:12:31 GMT 2023
|
PRIMARY | |||
|
100000183149
Created by
admin on Sat Dec 16 14:12:31 GMT 2023 , Edited by admin on Sat Dec 16 14:12:31 GMT 2023
|
PRIMARY | |||
|
KL-96
Created by
admin on Sat Dec 16 14:12:31 GMT 2023 , Edited by admin on Sat Dec 16 14:12:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT->ACTIVE ISOMER |
|
||
|
RACEMATE -> ENANTIOMER |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
||
|
METABOLITE ACTIVE -> PRODRUG |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
||
|
ACTIVE MOIETY |
|